Jennifer Good

Jennifer Good

Company: Trevi Therapeutics

Job title: Chief Executive Officer


A Novel Approach to Treating Pruritus in Prurigo Nodularis 11:30 am

Rationalizing the dual mechanism of action approach as both an antagonist (mu opioid receptor) & agonist (kappa opioid receptor) Providing fresh efficacy data from a phase 3 clinical trial Addressing the challenges with entering the prurigo nodularis marketRead more

day: Day 1 AM - Track A

Panel Discussion: Exploring the Dermatology Financing Landscape for 2022 & Beyond 8:00 am

What are large pharma looking for when partnering & how can smaller biotechs best prepare to partner How & where do you begin with developing a candidate for the rare disease space Debating how to position your drug candidate in the market where patients have failed other trialsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.